• Categories:News Information
• Author:
• Origin:
• Time of issue:2022-05-28
• Views:0

(Summary description)On March 24, 2022, during the special period of epidemic prevention and control, China Medical Devices Co., Ltd. (hereinafter referred to as "Sinopharm Devices") and Wuhan Mingde Biotechnology Co., Ltd. (hereinafter referred to as "Mingde Bio") held a strategic cooperation agreement Online signing ceremony. Zhang Wei, deputy general manager of Sinopharm, and Chen Lili, chairman of Mingde Bio, signed the contract on behalf of both parties. Li Jianfei, Assistant General Manager of Sinopharm Instruments, Hu Zhenyu, Deputy General Manager of the Western Division, Hu Pan, Director of Marketing Department, Yan Jipeng, Deputy Director, Li Xiaopeng, National Sales General Manager of Mingde Bio, Zhao Chen, General Manager of Immunization Product Line, and relevant personnel from the marketing departments of both parties attended the event. , and witnessed the signing ceremony.

Founded in 2008, Mingde Bio is a national high-tech enterprise specializing in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments as well as mobile ECG products. At present, the main business has covered 30 provinces, municipalities directly under the Central Government and autonomous regions across the country, and has achieved sales coverage in Asia, the European Union, South America and other regions. The company was listed on the Shenzhen Stock Exchange on July 10, 2018. On March 15, 2022, it became the first enterprise in Hubei Province to obtain the registration certificate for the domestic novel coronavirus antigen detection kit.

The signing of this strategic cooperation agreement has opened a new chapter in the comprehensive deepening of cooperation between Sinopharm and Mingde Bio. Professional supply chain channels, providing a full range of high-quality services for downstream distributors, hospitals and patients.